The Pavia consensus statement

Volberding, Paul A.; Murphy, Robert L.; Bárbaro, Giuseppe; Barbarini, Giorgio; Bruno, Raffaele; Cirelli, A; Currie, Peter; Lorenzo, G. Di; Fantoni, Massimo; Filice, G.; Galli, Massimo; Grisorio, Benvenuto; Moroni, Mauro; Recusani, F; Sacchi, Paolo; Scevola, D.; Stein, James H.; Torre, Donato; Vittecoq, D.

doi:10.1097/00002030-200304001-00021

Cited by 48 publications

(70 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Principles for the administration of dyslipidemias in the universal population, like those of the National Cholesterol Education Plan also stand for the origin for therapeutic recommendations in HIV infected persons, as defined by the HIV Medicine Alliance of the Infectious Disease Society of US and by the Pavia Agreement Declaration (Volberding P et al 2003).…”

Section: Conclusion and Recommendationsmentioning

confidence: 99%

Association of Highly Active Antiretroviral Treatment for HIV Disease and Metabolic Issues

Kolpepaj¹,

Shkurti²,

Nake³

et al. 2015

AJIS

View full text Add to dashboard Cite

show abstract

Section: Conclusion and Recommendationsmentioning

confidence: 99%

Association of Highly Active Antiretroviral Treatment for HIV Disease and Metabolic Issues

Kolpepaj¹,

Shkurti²,

Nake³

et al. 2015

AJIS

View full text Add to dashboard Cite

show abstract

“…For patients on HAART, it may be important to evaluate the traditional vascular risk factors and try to intervene in those that can be modified. Existing guidelines for the management of dyslipidemia in the general population, such as those of the National Cholesterol Education Program [30] , currently represent the basis for therapeutic recommendations in HIV-infected individuals, such as those reported by the HIV Medicine Association of the Infectious Disease Society of America and Adult AIDS Clinical Trial Groups and by the Pavia Consensus Statement [46,47] . In the absence of specific trial data, HIV patients who present with acute coronary syndromes should be treated according to the international guidelines.…”

Section: Hiv-associated Cardiology Issuesmentioning

confidence: 99%

“…Calcium channel blockers should be used with caution since they may interact with PIs. ACE inhibitors and angiotensin II receptor blockers may be recommended, but controlled clinical trials are still lacking in this subset of patients [47] . Hypoglycemic agents may have some role in managing glucose abnormalities.…”

Section: Hiv-associated Cardiology Issuesmentioning

confidence: 99%

“…Glitazones can be administered in combination with metformin. However, glitazones may interact with PIs and cannot be recommended for fat abnormalities alone, and metformin may cause lactic acidosis [47] . New insights in defining the cardiometabolic risk in patients with HAART-associated metabolic syndrome have been recently provided by the echocardiographic measurement of the epicardial adipose tissue.…”

Section: Hiv-associated Cardiology Issuesmentioning

confidence: 99%

See 1 more Smart Citation

Heart and HAART: Two sides of the coin for HIV-associated cardiology issues

Bárbaro¹

2010

WJC

Self Cite

View full text Add to dashboard Cite

The introduction of highly active antiretroviral therapy (HAART) has generated a contrast in the cardiac manifestations of acquired immunodeficiency syndrome. In developed countries, we have observed an approximately 30% reduction in the prevalence of human immunodeficiency virus (HIV)-associated cardiomyopathy, possibly related to a reduction of opportunistic infections and myocarditis. In developing countries, however, where the availablity of HAART is limited and the pathogenic impact of nutritional factors is significant, we have observed an approximately 32% increase in the prevalence of HIV-associated cardiomyopathy and a related high mortality rate from congestive heart failure. Also, some HAART regimens in developed countries, especially those including protease inhibitors, have been shown to cause, in a high proportion of HIV-infected patients, an iatrogenic metabolic syndrome (HIV-lipodystrophy syndrome) that is associated with an increased risk of cardiovascular events related to a process of accelerated atherosclerosis, even in young HIV-infected people. Careful cardiac screening is warranted for patients who are being evaluated for, or who are receiving, HAART regimens, particularly for those with known underlying cardiovascular risk factors. A close collaboration between cardiologists and infectious disease specialists is needed for decisions regarding the use of antiretrovirals, for a careful stratification of cardiovascular risk factors, and for cardiovascular monitoring of HIV-infected patients receiving HAART, according the most recent clinical guidelines.

show abstract

“…The following recommendations are based on the Pavia consensus statement for management of CVD in HIV infection, 149 recommendations of an International AIDS Society--USA panel 150 …”

Section: Management Of Cardiovascular Disease In Human Immunodeficienmentioning

confidence: 99%

The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment

Crook

2007

Ann Clin Biochem

View full text Add to dashboard Cite

This article was prepared at the invitation of the Clinical Sciences Review Committee of the Association for Clinical BiochemistryThe high global prevalence of human immunodeficiency virus (HIV) infection has been associated with high morbidity and mortality. The advent of highly active antiretroviral therapy (HAART) has, however, dramatically increased survival of patients infected with HIV. These patients now survive to develop metabolic complications of HIV infection and its treatment, including increased predisposition to atherosclerotic disease. HIV infection is normally associated with hypocholesterolaemia, hypertriglyceridaemia, low plasma HDL-cholesterol as well as alterations in other cardiovascular risk factors including inflammatory markers, clotting factors, homocysteine, apolipoproteins, lipoprotein (a), oxidative stress and non-esterified fatty acids. The use of HAART is, in particular, associated with dyslipidaemia and lipodystrophy with underlying insulin resistance and associated glucose intolerance. This article explores the metabolic abnormalities associated with increased cardiovascular risk that occur in HIV infection before and after antiretroviral therapy. The laboratory investigation and clinical management of HIVassociated dyslipidaemia and lipodystrophy will be discussed.

show abstract

The Pavia consensus statement

Cited by 48 publications

References 0 publications

Association of Highly Active Antiretroviral Treatment for HIV Disease and Metabolic Issues

Association of Highly Active Antiretroviral Treatment for HIV Disease and Metabolic Issues

Heart and HAART: Two sides of the coin for HIV-associated cardiology issues

The basis and management of metabolic abnormalities associated with cardiovascular risk in human immunodeficiency virus infection and its treatment

Contact Info

Product

Resources

About